Antithrombotics: Research and applications in healthcare
DOI:
https://doi.org/10.22517/25395203.25521Keywords:
Antithrombotics, Antiplatelets, Anticoagulants, Fibrinolysis, Blood coagulation, Cardiovascular eventsAbstract
Antithrombotics are drugs used to prevent the formation of blood clots, also known as thrombi. These clots can cause serious health problems, such as heart attacks or strokes. Different types of antithrombotics, such as antiplatelets and anticoagulants, are analyzed and their mechanisms of action are discussed. Additionally, the benefits and risks associated with the use of antithrombotics are examined. On the one hand, these drugs can reduce the risk of thrombotic events, which may be especially beneficial in patients with high-risk conditions, such as those who have suffered a heart attack or who have atrial fibrillation. On the other hand, the possible side effects of antithrombotics, such as the increased risk of bleeding, are also discussed and guidelines for their safe use in different clinical scenarios are provided. Additionally, monitoring and dose adjustment strategies for these medications are addressed to ensure their effectiveness and safety in patients.
Downloads
References
Altaf F, Wu S, Kasim V. Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy. Front Mol Biosci. 2021 May 28;8:680397. doi: 10.3389/fmolb.2021.680397.
Li T, Yuan D, Yuan J. Antithrombotic Drugs-Pharmacology and Perspectives. In: Wang, M. (Ed.) Coronary Artery Disease: Therapeutics and Drug Discovery. Advances in Experimental Medicine and Biology. 2020; 1177. Springer.
Undas A, Natorska J. Improving fibrinolysis in venous thromboembolism: impact of fibrin structure. Expert Rev. Hematol. 2019; 12 (8): 597-607.doi:
https://doi.org/10.1080/17474086.2019.1627193
Weitz J, Chan N.Novel antithrombotic strategies for treatment of venous thromboembolism.The American Society of Hematology. 2020; 135 (5): 351-359. doi:
https://doi.org/10.1182/blood.2019000919
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. 2020;75(23):2950–73. Available from: https://www.sciencedirect.com/science/article/pii/S0735109720350087
Dimitropoulos G, Rahim SMZ, Moss AS, Lip GYH. New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds. Expert Opin Investig Drugs. 2018 Jan;27(1):71-86. doi: 10.1080/13543784.2018.1416090
Little DHW, Robertson T, Douketis J, Dionne JC, Holbrook A, Xenodemetropoulos T, Siegal DM. Management of antithrombotic therapy after gastrointestinal bleeding: A mixed methods study of health-care providers. J Thromb Haemost. 2021 Jan;19(1):153-160. doi: 10.1111/jth.15111.
Lordan R, Tsoupras A, Zabetakis I. Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents. Blood Rev. 2021 Jan;45:100694. doi: 10.1016/j.blre.2020.100694.
Medcalf RL, Keragala CB, Myles PS. Fibrinolysis and COVID-19: A plasmin paradox. J Thromb Haemost. 2020 Sep;18(9):2118-2122. doi: 10.1111/jth.14960.
Haffouz A, Gargouri A & Basma H. Antiplatelet agents: an overview. J. Arab Soc. Med. Res. 2023; 18: 13-25.doi: 10.4103/jasmr.jasmr_35_22
Liampas I, Chlinos A, Siokas V, Brotis A, Dardiotis E. Assessment of the reporting quality of RCTs for novel oral anticoagulants in venous thromboembolic disease based on the CONSORT statement. J Thromb Thrombolysis. 2019 Nov;48(4):542-553. doi: 10.1007/s11239-019-01931-9.
Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov. 2020 May;19(5):333-352. doi: 10.1038/s41573-020-0061-0. Epub 2020 Mar 4. PMID: 32132678.
Montinari MR, Minelli S. From ancient leech to direct thrombin inhibitors and beyond: New from old. Biomed Pharmacother. 2022 May;149:112878. doi: 10.1016/j.biopha.2022.112878.
Zhang L, Li Z, Ye X, Chen Z, Chen ZS. Mechanisms of thrombosis and research progress on targeted antithrombotic drugs. Drug Discov Today. 2021 Oct;26(10):2282-2302. doi: 10.1016/j.drudis.2021.04.023
Chen Y, Hong J, Zhong H, Zhao Y, Li J, Shen W, Luo X, Shi H, Hu L, Liu J, Gao W. IL-37 Attenuates Platelet Activation and Thrombosis Through IL-1R8 Pathway. Circ Res. 2023 Apr 28;132(9):e134-e150. doi: 10.1161/CIRCRESAHA.122.321787.
Osuch E, Rasakanya T. Pharmacology and therapeutic uses of antiplatelet drugs.S. Afr. Gen. Pract. 2020;1 (3)1: 101-104. doi: https://doi.org/10.36303/SAGP.2020.3.0025
Soriano E, Gibbins J, Hughes C. Targeting platelet inhibition receptors for novel therapies: PECAM-1 and G6b-B.Platelets. 2021; 32 (6): 761-769.doi: 10.1080/09537104.2021.1882668
Tscharre M, Michelson AD, Gremmel T. Novel Antiplatelet Agents in Cardiovascular Disease. J Cardiovasc Pharmacol Ther. 2020 May;25(3):191-200. doi: 10.1177/1074248419899314.
Chan N, Weitz J. Antithrombotic Agents. New Directions in Antithrombotic Therapy.Circulation Research. 2019; 124 (3): 426-436. doi: https://doi.org/10.1161/CIRCRESAHA.118.313155
Hogwood J, Mulloy B, Lever R, Gray E, Page CP. Pharmacology of Heparin and Related Drugs: An Update. Pharmacol Rev. 2023 Mar;75(2):328-379. doi: 10.1124/pharmrev.122.000684.
Masotti L, Campanini M. Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics. Ital J Med [Internet]. 2013 Dec. 24 [cited 2024 May 20];7(s8):1-7. Available from: https://www.italjmed.org/ijm/article/view/itjm.2013.s8.1
Shnayder N, Petrova M, Bochanova E, Zimnitskaya O, Savinova A, Pozhilenkova E, et al. Pharmacogenetics of Direct Oral Anticoagulants [Internet]. Pharmacogenetics. IntechOpen; 2021. Available from: http://dx.doi.org/10.5772/intechopen.
Chiang YC, Wu YS, Kang YF, Wang HC, Tsai MC, Wu CC. 3,5,2',4'-Tetramethoxystilbene, a fully methylated resveratrol analog, prevents platelet aggregation and thrombus formation by targeting the protease-activated receptor 4 pathway. Chem Biol Interact. 2022 Apr 25;357:109889. doi: 10.1016/j.cbi.2022.109889.
Liu Y, Xin G, Li F, Wang Y, Li S, Dong Y, Zhang K, Feng L, Zhang B, Huang W. SIRT6 inhibits platelet activation and thrombosis by regulating PCSK9/MAPK signaling. Research Square; 2023; doi: 10.21203/rs.3.rs-2503959/v1
Longstaff C. Measuring fibrinolysis: from research to routine diagnostic assays. J Thromb Haemost. 2018 Apr;16(4):652-662. doi: 10.1111/jth.13957.
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh AM. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018 Nov;16(11):1289-1303. doi: 10.6004/jnccn.2018.0084.
Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf. 1994 May;10(5):381-94. doi: 10.2165/00002018-199410050-00003.
Ibrahim MA, Masoud HMM. Purification and characterization of thrombin from camel plasma: interaction with camel tick salivary gland thrombin inhibitor. J Genet Eng Biotechnol. 2023 Jan 23;21(1):7. doi: 10.1186/s43141-023-00464-2.
Mehuys E, De Backer T, De Keyser F, Christiaens T, Van Hees T, Demarche S, Van Tongelen I, Boussery K. Prevalence and management of drug interactions between nonsteroidal anti-inflammatory drugs and antithrombotics in ambulatory care. Br J Clin Pharmacol. 2022 Aug;88(8):3896-3902. doi: 10.1111/bcp.15288.
Dager WE, Trujillo TC, Gilbert BW. Approaches to Precision-based Anticoagulation management in the critically Ill. Pharmacotherapy. 2023 Nov;43(11):1221-1236. doi: 10.1002/phar.2868.
Dager WE, Ansell J, Barnes GD, Burnett A, Deitelzweig S, Minichiello T, Triller D, Kaatz S. "Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy": Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance. Jt Comm J Qual Patient Saf. 2020 Mar;46(3):173-180. doi: 10.1016/j.jcjq.2019.12.004.
Mohamad T, Jyotsna F, Farooq U, Fatima A, Kar I, Khuwaja S, Memon UA, Kumari V, Puri P, Aslam ZM, Elder Z, Varrassi G, Paladini A, Khatri M, Kumar S, Muzammil MA. Individualizing Medicinal Therapy Post Heart Stent Implantation: Tailoring for Patient Factors. Cureus. 2023 Aug 23;15(8):e43977. doi: 10.7759/cureus.43977.
Ballestri S, Romagnoli E, Arioli D, Coluccio V, Marrazzo A, Athanasiou A, Di Girolamo M, Cappi C, Marietta M, Capitelli M. Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review. Adv Ther. 2023 Jan;40(1):41-66. doi: 10.1007/s12325-022-02333-9.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
Abouhussein DMN, Bahaa El Din Mahmoud D, Mohammad F E. Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases. J Liposome Res. 2019 Dec;29(4):399-412. doi: 10.1080/08982104.2019.1576732.
Lichota A, Szewczyk EM, Gwozdzinski K. Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds. Int J Mol Sci. 2020 Oct 27;21(21):7975. doi: 10.3390/ijms21217975.
Downloads
-
Vistas(Views): 94
- PDF (Español (España)) Descargas(Downloads): 56
- PDF Descargas(Downloads): 1
Published
How to Cite
Issue
Section
License
Cesión de derechos y tratamiento de datos
La aceptación de un artículo para su publicación en la Revista Médica de Risaralda implica la cesión de los derechos de impresión y reproducción, por cualquier forma y medio, del autor a favor de Facultad de Ciencias de la Salud de la Universidad Tecnológica de Pereira. 1995-2018. Todos los derechos reservados ®
por parte de los autores para obtener el permiso de reproducción de sus contribuciones. La reproducción total o parcial de los trabajos aparecidos en la Revista Médica de Risaralda, debe hacerse citando la procedencia, en caso contrario, se viola los derechos reservados.
Asimismo, se entiende que los conceptos y opiniones expresados en cada trabajo son de la exclusiva responsabilidad del autor, sin responsabilizarse ni solidarizarse, necesariamente, ni la redacción, ni la editorial.
Es responsabilidad de los autores poder proporcionar a los lectores interesados copias de los datos en bruto, manuales de procedimiento, puntuaciones y, en general, material experimental relevante.
Asimismo, la Dirección de la revista garantiza el adecuado tratamiento de los datos de carácter personal